Physician profile
Mary Sturm
NPI 1437279924
$5,074.60
in general payments reported to CMS, 2019-2025
22 companies · $1,433 in 2025
The $1,433 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $308 · 2020: $362 · 2021: $853 · 2022: $410 · 2023: $705 · 2024: $1,004 · 2025: $1,433.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,116 · Honoraria: $25.59.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,116.10 |
| Honoraria | $25.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sun Pharmaceutical Industries INC. | $590.96 | 2020-2025 | Cequa, Xelpros |
| Johnson & Johnson Surgical Vision, INC. | $567.42 | 2019-2025 | Tecnis Iol, Tecnis Iol, Catalys System |
| Alcon Vision LLC | $539.23 | 2021-2025 | Clareon Panoptix Pro, Clareon, Simbrinza |
| Abbvie INC. | $493.17 | 2022-2025 | Alphagan P, Lumigan, Durysta |
| Tarsus Pharmaceuticals, INC. | $447.56 | 2024-2025 | Xdemvy |
| Glaukos Corporation | $409.25 | 2021-2025 | Photrexa Viscous and Photrexa, Idose, Ce-Marked Kxla System |
| Bausch & Lomb Americas INC. | $325.85 | 2023-2025 | Miebo, Xiidra, Vyzulta |
| Allergan, INC. | $301.23 | 2019-2022 | |
| Rxsight INC | $212.57 | 2022-2024 | Rxsight Light Delivery Device (Ldd), Rxsight Contact Lens, Rxsight Injector Handpiece |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $188.57 | 2019-2021 | |
| Dompe US, INC. | $173.22 | 2024-2025 | Oxervate |
| Kala Pharmaceuticals, INC. | $155.75 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $153.16 | 2020-2023 | Xiidra |
| Biotissue Holdings INC. | $126.56 | 2023 | |
| The Cameron-Ehlen Group, INC. | $120.06 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $109.77 | 2022-2023 | Tepezza |
| Shire North American Group INC | $47.98 | 2019 | |
| Aerie Pharmaceuticals, INC. | $36.68 | 2020 | |
| Ocular Therapeutix, INC. | $24.40 | 2025 | Dextenza |
| Astellas Pharma US INC | $19.40 | 2025 | Izervay |
| Oyster Point Pharma, INC. | $16.95 | 2022 | |
| Sight Sciences, INC. | $14.86 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mary Sturm listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.